Response Genetics Inc, a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced the addition of Michael B. McNulty as the Company’s chief operating officer.

In his role as COO, McNulty brings extensive experience in managing the scale-up of laboratory operations and testing services. Effective July 12, 2010, McNulty will be responsible for the Company’s operations, strategy and corporate development.

“I am pleased to welcome Michael to Response Genetics,” said Kathleen Danenberg, president and CEO of Response Genetics. “With more than 25 years of commercial laboratory and diagnostic industry experience, Michael brings a wealth of knowledge to our company at a time of significant growth. And, with a successful track record of helping companies become recognized leaders in the diagnostic space, we look forward to an exciting future.”

Most recently, McNulty was general manager, Diagnostics at Agilent Technologies Inc, a premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis with annual net revenue of $4.5 billion.

McNulty also held the position of vice president, Laboratory Operations at Berkeley HeartLab Inc (now Celera Diagnostics), where he was responsible for the scale-up of laboratory operations and development of new laboratory services. As senior vice president, Sales, Marketing and Business Development at THAUMDX LLC, he was responsible for managing product launches and business development initiatives. McNulty spent fourteen years with SmithKline Beecham Healthcare Services, where he ran the company’s Chicago-based reference laboratory prior to its becoming Quest Diagnostics. McNulty received a Bachelor of Science degree in microbiology and a Bachelor of Science degree in biochemistry from San Jose State University.

Commenting on his appointment, McNulty said, “I am excited to join a dynamic company like Response Genetics where I can make a significant impact, both in the development of the business and in bringing to market products that make a difference in people’s lives. Based on its record of growth and unique technology platform, I look forward to helping the company reach its full potential.”

Source: Response Genetics